tbuckley/cabot-search huggingface dataset:
BI14: Multiple autoimmune bullous disorders arising secondary to immune checkpoint blockade
Journal: British Journal of Dermatology (2021)

KP-1), CD163 and CD14 but negative for CD3 and other Tcell markers, performed to exclude involvement by ATLL.HTLV-1 serology was negative.Bone marrow trephine biopsy demonstrated 75% monocytic blasts showing immunopositivity for CD68, CD163 and lysozyme.However, her bone marrow was 100% donor (total white cell).Similarly, peripheral blood chimerism studies were 100% donor (total white cell and T cell).Taking these findings together, a diagnosis of donor-derived AML with monocytic differentiation was made.She was treated with a second haematopoietic stem cell transplant from a 9/10 matched unrelated donor.Unfortunately, she later died from sepsis.To our knowledge, this is the first case of donor-derived AML following a haploidentical HSCT for HTLV-1 ATLL, which was originally identified with a cutaneous presentation.Owing to the rarity of this situation, the implications for the donor (patient's daughter) are unclear, although her blood count remains normal.This case highlights the importance of histological assessment of persistent cutaneous GVHD to identify malignancies in high-risk HSCT recipients. BI13An audit to review the uptake of recommended vaccinations in patients with psoriasis prescribed immunosuppressing medications
THE QUESTION OF REMOVAL.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dementia
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abdominal Surgery
Authors: Arthur W. Allen
Journal: New England Journal of Medicine (1945)

ADVANCES in abdominal surgery during the past year have been evaluated. Many of the papers relate to the surgery of trauma and these will not be taken into consideration except when such information may be applicable to problems of civil practice. All reports cannot be included, but many of the timely subjects will be discussed.General Considerations Anesthesia Arrowood and Foldes1 have modified Lemmon's2 method of continuous spinal anesthesia. These authors report the use of a continuous-drop method of maintaining spinal anesthesia in approximately 40 cases. A recent personal communication reveals that over 60 patients have been anesthetized by this . . .
Abstract 2159: Medial Necrosis Due to Sirolimus-Eluting Stent Implantation in Human Coronary Arteries
Authors: Katsumi Inoue, Kazuaki Mitsudo, Masakiyo Nobuyoshi
Journal: Circulation (2007)

Background: Sirolimus-eluting stents (SES) have been proven to reduce the rates of restenosis by a striking inhibition of neointimal hyperplasia. However, unusual vessel responses to SES, such as late-acquired incomplete stent apposition (ISA) have been observed, and the precise mechanism of late ISA has not been clarified. Methods and Results: To examine the mechanism of late ISA, the temporal mode of vascular responses after SES (3 days (D) to 12 months (M), 14 lesions) and bare metal stent (BMS; 2 D to 12 M, 24 lesions) implantation was investigated histopathologically in necropsied coronary arteries. In arteries that had been implanted with SES for 4 M, the stent struts were focally covered by thin membranous tissue mainly composed of fibrin deposition. Complete coverage of BMS by neointimal tissue composed of smooth muscle cells (SMC) and extracellular matrix (ECM) was documented after 1.5 M. Only mild neointimal thickening with focal endothelialization was observed around the circumference of the lumen at the stented site of atherosclerotic plaque-free segment in 4 of 9 lesions after 4 to 12 M. In these lesions, expansion of the stent strut forced the struts contiguous to the medial layer. Remarkable loss of medial SMCs was evident not only at the sites of the stent struts that had contacted and focally compressed the medial layer, but also at the sites where there was bowing of the media into the intima between the struts. In contrast, only restricted and incomplete medial SMC depletion was observed in the BMS segments where struts compressed the medial layer. We could observe that the medial SMC depletion was present only in the portions where SES struts directly contacted the medial wall layers. Depletion of medial SMC was not clearly observed even in DES segment between 3 D and 1 M. Conclusions: Therefore, it is possible that these phenomena concerning elimination of medial SMCs were elicited by not only mechanical injury due to stent expansion but also by the pharmacological effect of sirolimus itself. The cytostatic effects of sirolimus on neointimal formation could be complicated by these local cytotoxic effects followed by a decrease in arterial wall tension, causing stent malapposition.
Positive Views of Retirement Communities
Authors: Joseph C. Sloan
Journal: Annals of Internal Medicine (1993)

Letters1 May 1993Positive Views of Retirement CommunitiesJoseph C. Sloan, MDJoseph C. Sloan, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-9-199305010-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Eight years ago, my wife and I moved into Golden Acres, the subject of recent criticism in Annals [1]. Like most couples our age, independence had always been the name of the game. We were accustomed to giving supportnot getting it. This move would be something very differentliving in an apartment among strangers at first, but where others of like mind were trying, as we were, to secure a reasonable future against, as Shakespeare put it, the slings and arrows of outrageous fortune. We found bright people, interesting people, private people, lonely people, ailing people, cheerful people, ...REFERENCE1. Greganti MA. Life care at Golden Acres. 1992; 117:869-71. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1993Volume 118, Issue 9Page: 751-752KeywordsConsciousnessForecastingGames Issue Published: 1 May 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
Authors: Chunyan Lan, Xin Huang, Jing-Xian Shen, Yin Wang, Ying Xiong, Jundong Li, Xinping Cao, Yanhong Deng, Mian He, Guorong Zou, Xiaodi Wang
Journal: Journal of Clinical Oncology (2020)

6021 Background: Camrelizumab is a fully humanized, monoclonal antibody against PD-1. We aimed to assess the efficacy and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor targeting VEGFR2, in patients with advanced cervical cancer. Methods: In this open-label, single-arm, phase 2 study done at four centres in China, eligible patients were aged 18–70 years, had an ECOG performance status of 0 or 1, progressed after at least one line of systemic chemotherapy for metastatic, recurrent or persistent cervical cancer, and had measurable disease. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once daily. Treatment continued until disease progression, unacceptable toxicity, and withdrawal of consent. The primary endpoint was the objective response rate (ORR) assessed by RECIST version 1.1. An optimal Simon two-stage design was employed to test the null hypothesis of a 17% ORR versus 35% alternative (1-sided alpha 0.10, 80% power), if &gt; 3 responses out of the first 16 patients were observed, then the study would continue to enroll a total of 44 patients. Results: Between Jan 21st, 2019, and Aug 1st, 2019, 45 patients were enrolled and received study treatment (safety population). The median age was 51 (range, 33–67) years. Median previous treatment lines were 2 (range, 1–4). As of Jan 22, 2020, median follow-up was 9.2 months (range, 2.4–12.2). 25 (59.5%; 95%: CI 44.7–74.4) of 42 patients who had at least one post-baseline tumor assessment (efficacy evaluable population) achieved an objective response, including two (4.8%) complete response, and 23 (54.8%) partial response. Median duration of response was not reached. The disease control rate was 88.1% (37/42). Median progression-free survival (PFS) was 7.6 months (95% CI: 5.8–not reached). 31 (68.9%) patients had grade ≥ 3 treatment-related adverse events (TRAEs). Grade ≥ 3 TRAEs occurring in ≥ 5% of patients were hypertension (24.4%), anemia (20.0%), fatigue (15.6%), γ-glutamyltransferase increased (13.3%), neutropenia (6.7%), and thrombocytopenia (6.7%). In post-hoc analyses, objective response was noted in 20 (69%) of 29 patients with PD-L1-positive tumors, and in 5 (50.0%) of 10 patients with PD-L1-negative tumors (Chi-square test, P = 0.281). PFS was longer in patients with PD-L1-positive tumors than patients with PD-L1-negative tumors (median PFS: 9.6 versus 5.3 months; log-rank test, P = 0.017). Conclusions: Camrelizumab plus apatinib showed promising antitumor activity and tolerable toxicities in patients with advanced cervical cancer. Clinical trial information: NCT03816553.
Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients
Authors: Aytug Kizilors, Patrick Harrington, Sophie Jackson, Nicholas Lea, Joel Newman, Richard Gale, Sandra Hassan, Evangelia Dimitriadou, Elena Crisà, Luke Ficinski, Isabel Sa, Anita Arasaretnam, Vijayavalli Dhanapal, Timothy Corbett, Robin M. Ireland, Antonio Pagliuca, Ghulam J. Mufti, Hugues De Lavallade
Journal: Blood (2018)
ANTISCORBUTICS
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinicopathological conference. A patient's life.
Journal: BMJ (1975)

4-3 x 109/1 and 158 x 109/1 and red cell survival studies showed a greatly diminished half life (6-1 days) with significant sequestration in the spleen.A 99mTc colloid scan showed that the spleen was slightly enlarged and splenectomy was performed on 2 July 1974.The spleen was friable and after operation she developed a left subphrenic
PHYSICAL DEVELOPMENT IN AMERICA.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Uremia
Authors: John P. Merrill, Constantine L. Hampers
Journal: New England Journal of Medicine (1970)

Vascular AbnormalitiesThe genesis of congestive heart failure in uremia includes a number of factors, some of which are obvious and some more obscure. Anemia, hypertension, atherosclerosis and vascular calcification in advanced renal failure obviously contribute. Increased intravascular volume and plasma volume are certainly involved, but the correlation is not an exact one.83 "High-output" congestive heart failure has been noted in a number of patients3 and may be in part due to anemia. On the other hand, the metabolic abnormalities of uremia are many, and some of the characteristics of this state of high-output failure suggest that it may have . . .
Appearing and Disappearing
Authors: E. J. H.
Journal: Annals of Internal Medicine (1965)

Editorials1 November 1965Appearing and DisappearingE. J. H.E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-5-899 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFor many years the Annals has been publishing a monthly list of Books Recently Received, made up of the titles of those sent to us for review or listing. We have not been satisfied that this list was useful. Owing to the publishing schedule peculiar to a monthly, books were often reviewed in the same number in which they were also listed as "recently received." Furthermore, a book could not be listed in the ANNALS until at least 2 months after its arrival at the editorial office.Expecting that a more timely listing will be more useful to medical librarians,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1965Volume 63, Issue 5Page: 899-900 ePublished: 1 December 2008 Issue Published: 1 November 1965 PDF downloadLoading ...
Minimal Role of Enhanced Cell Proliferation in Skin Tumor Promotion by Mirex: A Nonphorbol Ester-Type Promoter
Authors: Sharon A. Meyer, Glenda J. Moser, Nancy A. Monteiro-Riviere, Robert C. Smart
Journal: Environmental Health Perspectives (1993)

Mirex, a chlorinated hydrocarbon previously used as a systemic insecticide and flame retar- dant, is a nongenotoxic hepatocarcinogen in both rats and mice.In liver, mirex induced bio- chemical responses and hyperplasia characteristic of increased cell proliferation, which is con- sistent with its role as a liver tumor promoter.We have recently shown that mirex is a potent nonphorbol ester-type skin tumor promoter in 7, 12-dimethylbenz[a]anthracene (DMBA)-initiat- ed mice.However, unlike its effect in liver, a single topical application of mirex to skin does not induce the acute biochemical responses, such as increased epidermal DNA synthesis and ornithine decarboxylase activity, indicative of increased cell proliferation.Multiple topical applications of mirex over a 1 month period induced only a minimal increase in the number of epidermal nucleated cell layers, which contrasts with definitive hyperplasia induced by a com- parable tumor-promoting dose of 12-0-tetradecanoylphorbol-13-acetate (TPA).Collectively, these data indicated that mirex is promoting through a novel mechanism.Further evidence that mirex promotes tumors through a mechanism distinct from that of the prototypical skin tumor promoter, TPA, was obtained by examining the effect of their simultaneous co-treatment.The co-application of mirex and TPA yielded a tumor multiplicity greater than the sum of the responses of each promoter individually.In summary, our results demonstrate that mirex, a carcinogenic and hyperplastic agent in liver, is also a very effective tumor promoter in mouse skin, but suggest that mirex operates via a novel mechanism in skin that may involve only a minimal role for enhanced cell proliferation.
Klinika eksperimentalnogo B-avitaminoza
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contents
Authors: George Bray, Olivia Farr, Michelle Camp, Christos Mantzoros, Ji-Sun Hwang, Ji-Won Park, Jia Liu, Yuan Xu, Yanjin Hu, Guang Wang, Daniela Rubin, Susan Clark, Jason Ng, Diobel Castner, Andrea Haqq, Daniel Judelson
Journal: Metabolism (2015)
THE ANTIVIVISECTION BILL IN CONGRESS.
Authors: D S Lamb
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Biological Symposia. Vol. II. Speciation; Defense Mechanisms in Plants and Animals; Biological Basis of Social Problems; Regeneration . Edited by Jaques Cattell. With a foreword by George A. Baitsell, Ph.D. 8°, cloth, 270 pp., with 13 illustrations and 1 table. Lancaster, Pennsylvania: The Jaques Cattell Press, 1941. $2.50.
Journal: New England Journal of Medicine (1941)
Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).
Authors: Kirsten Fischer, Stephan Stilgenbauer, Carmen D. Schweighofer, Jasmin Renschler, Raymonde Busch, Michael Kiehl, Leopold Balleisen, Michael Eckart, Anna M. Fink, Sebastian Boettcher, Matthias Ritgen, Michael Kneba, Peter Staib, Hartmut Doehner, Barbara F. Eichhorst, Michael Hallek, Clemens-Martin Wendtner
Journal: Blood (2007)
Sedating Drugs and Neuromuscular Blockade During Mechanical Ventilation
Authors: Pamela G. Dulin
Journal: JAMA (1992)

<h3>To the Editor.</h3> —The recent article by Hansen-Flaschen et al<sup>1</sup>that discussed the use of sedating drugs and neuromuscular blocking agents in the intensive care unit (ICU) is timely. In September 1990, we instituted a new protocol at Florida Hospital Medical Center in Orlando. This protocol resulted from our unsatisfactory experiences with both pancuronium and vecuronium when used in mechanically ventilated patients; neither agent was predictably reversible. We have successfully treated more than 60 patients with continuous infusions of atracurium besylate in conjunction with various sedating agents and careful monitoring with a peripheral nerve stimulator. We have experienced no untoward or unexpected effects and have, on every occasion, been able to readily recover these patients within an hour of discontinuing the infusion. Our protocol is based on an initial bolus dose of 0.3 to 0.5 mg/kg, immediately followed by an infusion, usually in the range of 5 to 15
Correction: SIX1 Promotes Tumor Lymphangiogenesis by Coordinating TGFβ Signals That Increase Expression of VEGF-C
Authors: Dan Liu, Li Li, Xiao-Xue Zhang, Dong-Yi Wan, Bi-Xin Xi, Zheng Hu, Wen-Cheng Ding, Da Zhu, Xiao-Li Wang, Wei Wang, Zuo-Hua Feng, Hui Wang, Ding Ma, Qing-Lei Gao
Journal: Cancer Research (2019)